BackMarker Therapeutics Overview

Marker Therapeutics Minority Interest

Latest minority interest for MRKR: $0.

Get informed when a big investor buys or sells

+ Follow
Minority Interest
$0.00

Peer trimmed avg / median

Loading

Marker Therapeutics Minority Interest History

Loading

Marker Therapeutics vs. peers: Minority Interest Comparison

Loading

Marker Therapeutics Minority Interest Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Marker Therapeutics (MRKR) FAQ

As of the most recent data (June 2026), MRKR shows a minority interest of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, MRKR's minority interest is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Marker Therapeutics is outperforming or lagging.

Tracking MRKR's minority interest over time shows whether Marker Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this minority interest page, Stockcircle has Marker Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect minority interest (currently $0) with ownership activity and broader fundamentals.

Marker Therapeutics's minority interest is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.